Pathstone Holdings
ANIP icon

Pathstone Holdings’s ANI Pharmaceuticals ANIP Stock Holding History

Pathstone Holdings’s Portfolio ANIP Stock Details ANIP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-2,692
Closed -$247K – 2239
2025
Q3 		$247K Buy
+2,692
New +$220K ﹤0.01% 2112

Other funds holding ANIP

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
GACM
Global Alpha Capital Management Montreal, Quebec, Canada $1.67B AUM 35.09% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Pathstone Holdings's ANIP Position: Q4 2025 in Review

Pathstone Holdings sold out of ANI Pharmaceuticals (ANIP) in Q4 2025, closing a stake of 2,692 shares — an estimated $247K sold.

Pathstone Holdings first reported a position in ANIP in Q3 2025 and held it in 1 quarter. The position peaked at $247K in Q3 2025. 284 funds tracked by Wall St. Rank hold ANIP as of Q4 2025.

  • Pathstone Holdings reported no remaining ANI Pharmaceuticals position as of Q4 2025 after selling out during the quarter.
  • Pathstone Holdings sold 2,692 ANI Pharmaceuticals shares in Q4 2025, an estimated $247K.
  • Pathstone Holdings first reported a position in ANI Pharmaceuticals in Q3 2025 and held it in 1 quarter.
  • Pathstone Holdings's ANI Pharmaceuticals position peaked at $247K in Q3 2025.
  • 284 funds tracked by Wall St. Rank held ANI Pharmaceuticals as of Q4 2025.

Based on Pathstone Holdings's 13F filing for Q4 2025, filed 13 Feb 2026.